Drug Trial News

RSS

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.

17 Oct 2012

Chloride-restrictive intravenous strategy may decrease incidence of AKI among critically ill patients

In a pilot study assessing the effect of different levels of chloride in intravenous fluids administered to critically ill patients in an intensive care unit, restricting the amount of chloride administration was associated with a significant decrease in the incidence of acute kidney injury and the use of renal replacement therapy, according to a study in the October 17 issue of JAMA.

17 Oct 2012

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

Resverlogix Corp. today announced that it has initiated an exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

17 Oct 2012

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

15 Oct 2012

Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012.

15 Oct 2012

No link between folic acid, vitamin B6 and 12 and increased risk of colorectal adenoma

Combined folic acid, vitamin B6 and vitamin B12 supplements had no statistically significant effect on the risk of colorectal adenoma among women who were at high risk for cardiovascular disease, according to a study published October 12 in the Journal of the National Cancer Institute.

15 Oct 2012

GlaxoSmithKline to make clinical trial data available to other researchers

GlaxoSmithKline (GSK) CEO Andrew Witty "said on Thursday detailed data from its clinical trials would be made available to other researchers," Reuters reports, adding, "That would include anonymized patient-level results that sit behind clinical trials of approved and failed drugs."

15 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

Study compares two drug combinations for use as deep sedation during oral surgery

The ideal sedative for oral surgery should make the patient comfortable during the surgery and should wear off quickly enough that the patient can leave the dental chair soon after the procedure. Finding the best plan of anesthetic treatment is essential to the success of dental procedures such as the extraction of wisdom teeth.

12 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

12 Oct 2012

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.

12 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

11 Oct 2012

Women respond much better than men to treatment of CFL with rituximab

Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the highly respected journal "Haematologica".

11 Oct 2012

Drug Trial News

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Chloride-restrictive intravenous strategy may decrease incidence of AKI among critically ill patients

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

No link between folic acid, vitamin B6 and 12 and increased risk of colorectal adenoma

GlaxoSmithKline to make clinical trial data available to other researchers

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Study compares two drug combinations for use as deep sedation during oral surgery

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

Women respond much better than men to treatment of CFL with rituximab

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News